The development of immunotherapy in oncology builds upon many years of scientific
investigation into the cellular mechanics underlying interactions between tumor cells and …

Several immune checkpoint blockades (ICBs) capable of overcoming the
immunosuppressive roles of the tumor immune microenvironment have been approved by …

Radiation therapy (RT) activates multiple immunologic effects in the tumor microenvironment
(TME), with diverse dose-response relationships observed. We hypothesized that, in …

Immune‑checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed
cell death receptor‑1, is an emerging treatment for metastatic non‑small cell lung cancer …

Background The impact of transarterial radioembolization (TARE) of breast cancer liver
metastasis (BCLM) on antitumor immunity is unknown, which hinders the optimal selection …

Numerous dose rate effects have been described over the past 6–7 decades in the radiation
biology and radiation oncology literature depending on the dose rate range being …

The mainstays of radiation therapy include external beam radiation therapy (EBRT) and
internally implanted radiation, or brachytherapy (BT), all with distinct benefits and risks in …

Simple Summary Immune checkpoint inhibitors have become the standard of care therapy in
a multimodal setting for recurrent/metastatic HNSCC. Multiple clinical trials have recently …

Background To determine whether combining brachytherapy with immunotherapy is safe in
prostate cancer (PCa) and provides synergistic effects, we performed a Phase I/II trial on the …

Recent preclinical and clinical studies have elucidated mechanisms whereby radiation
therapy influences the anti-tumor immune response. Immunogenic cell death and …